FDA Urged To Change OTC Monograph System, But Not In Midstream
This article was originally published in The Tan Sheet
Executive Summary
“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.
You may also be interested in...
Firms Consult FDA, Add “Do Not Use” For Under 4 To Pediatric Cold Products
Over-the-counter pediatric cough/cold products relabeled "do not use" for children under 4 will reach shelves in the next few weeks in a voluntary program manufacturers coordinated with FDA
FDA Floats Eliminating Multi-Ingredient Pediatric Cold Products
FDA suggests the drug industry consider making pediatric cough/cold formulations available only as single-ingredient products, according to an agency report
FDA Review Of Children’s Cough/Cold OTCs Has Broader Implications
FDA's review of children's over-the-counter cough/cold products will address the broader issue of whether extrapolating pediatric doses from adult dosing data is appropriate